Triiodothyronine (T3) upregulates the expression of proto-oncogene TGFA independent of MAPK/ERK pathway activation in the human breast adenocarcinoma cell line, MCF7

Objective: To verify the physiological action of triiodothyronine T3 on the expression of transforming growth factor α (TGFA) mRNA in MCF7 cells by inhibition of RNA Polymerase II and the MAPK/ERK pathway. Materials and methods: The cell line was treated with T3 at a physiological dose (10-9M) for 1...

Descripción completa

Detalles Bibliográficos
Autores: Silva, Tabata M. [UNESP], Moretto, Fernanda C. F. [UNESP], De Sibio, Maria T. [UNESP], Gonçalves, Bianca M. [UNESP], Oliveira, Miriane [UNESP], Olimpio, Regiane M. C. [UNESP], Oliveira, Diego A. M. [UNESP], Costa, Sarah M. B. [UNESP], Deprá, Igor C. [UNESP], Namba, Vickeline [UNESP], Nunes, Maria T., Nogueira, Célia R. [UNESP]
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:Brasil
Institución:Universidade Estadual Paulista (UNESP)
Repositorio:Repositório Institucional da UNESP
Idioma:inglés
OAI Identifier:oai:repositorio.unesp.br:11449/187698
Acceso en línea:http://dx.doi.org/10.20945/2359-3997000000114
http://hdl.handle.net/11449/187698
Access Level:acceso abierto
Palabra clave:Breast cancer
Gene expression
Nongenomic actions
Thyroid hormone
Descripción
Sumario:Objective: To verify the physiological action of triiodothyronine T3 on the expression of transforming growth factor α (TGFA) mRNA in MCF7 cells by inhibition of RNA Polymerase II and the MAPK/ERK pathway. Materials and methods: The cell line was treated with T3 at a physiological dose (10-9M) for 10 minutes, 1 and 4 hour (h) in the presence or absence of the inhibitors, α-amanitin (RNA polymerase II inhibitor) and PD98059 (MAPK/ERK pathway inhibitor). TGFA mRNA expression was analyzed by RT-PCR. For data analysis, we used ANOVA, complemented with the Tukey test and Student t-test, with a minimum significance of 5%. Results: T3 increases the expression of TGFA mRNA in MCF7 cells in 4 h of treatment. Inhibition of RNA polymerase II modulates the effect of T3 treatment on the expression of TGFA in MCF7 cells. Activation of the MAPK/ERK pathway is not required for T3 to affect the expression of TGFA mRNA. Conclusion: Treatment with a physiological concentration of T3 after RNA polymerase II inhibition altered the expression of TGFA. Inhibition of the MAPK/ERK pathway after T3 treatment does not interfere with the TGFA gene expression in a breast adenocarcinoma cell line.

Similares en LA Referencia